Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | CYP4Cod1 | 0.0012 | 0.0824 | 0.1944 |
Leishmania major | cytochrome p450-like protein | 0.0012 | 0.0824 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0012 | 0.0824 | 0.1944 |
Echinococcus granulosus | intermediate filament protein | 0.0026 | 0.4238 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0013 | 0.099 | 0.2336 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.0875 | 0.2065 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0012 | 0.0824 | 0.5 |
Echinococcus multilocularis | lamin dm0 | 0.0026 | 0.4238 | 1 |
Onchocerca volvulus | 0.0026 | 0.4238 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.4238 | 1 |
Echinococcus granulosus | lamin dm0 | 0.0026 | 0.4238 | 1 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0014 | 0.1323 | 0.3123 |
Echinococcus granulosus | lamin | 0.0026 | 0.4238 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0026 | 0.4238 | 1 |
Trypanosoma brucei | cytochrome P450, putative | 0.0012 | 0.0824 | 0.5 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0012 | 0.0824 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.4123 | 0.9729 |
Brugia malayi | cytoplasmic intermediate filament protein | 0.0014 | 0.1323 | 0.1463 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.0875 | 0.2065 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0026 | 0.4238 | 1 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0012 | 0.0824 | 0.1944 |
Onchocerca volvulus | 0.0026 | 0.4238 | 0.5 | |
Echinococcus multilocularis | musashi | 0.0026 | 0.4238 | 1 |
Loa Loa (eye worm) | intermediate filament protein | 0.0026 | 0.4238 | 1 |
Brugia malayi | intermediate filament protein | 0.0026 | 0.4238 | 1 |
Mycobacterium ulcerans | cytochrome P450 185A4 Cyp185A4 | 0.0012 | 0.0824 | 0.5 |
Echinococcus multilocularis | lamin | 0.0026 | 0.4238 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.